Open AccessImproved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Author(s) -
Keith T. Flaherty,
Caroline Robert,
Peter Hersey,
Paul Nathan,
Claus Garbe,
Mohammed Milhem,
Lev Demidov,
Jessica C. Hassel,
Piotr Rutkowski,
Peter Mohr,
Reinhard Dummer,
Uwe Trefzer,
James Larkin,
Jochen Utikal,
Brigitte Dréno,
Marta Nyakas,
Mark R. Middleton,
Jürgen C. Becker,
Michelle Casey,
Laurie Sherman,
Frank Wu,
Danièle Ouellet,
AnneMarie Martin,
Kiran Klaus Patel,
Dirk Schadendorf
Publication year - 2012
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1203421
Subject(s) - trametinib , medicine , dabrafenib , hazard ratio , dacarbazine , mek inhibitor , chemotherapy , oncology , melanoma , vemurafenib , mucositis , gastroenterology , confidence interval , cancer research , cancer , kinase , mapk/erk pathway , metastatic melanoma , biology , microbiology and biotechnology
Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom